Organon gains Chiron HIV assay rights
Chiron Corp of the USA had granted Organon Teknika, a subsidiary of AkzoNobel, a worldwide, semi-exclusive license under the company's patents on HIV in assays claiming the detection of nucleic acid sequences for use in clinical diagnostics, excluding blood screening.
The financial terms of the deal are not disclosed, other than that Chiron will receive royalties based on a percentage of Organon Teknika's net sales of both current and future products, subject to certain minimum royalties calculated as a fixed amount per test sold.
The agreement will enable Organon Teknika to continue to manufacture and sell probe-based HIV diagnostics products, including its NucliSens HIV-1 viral load and NucliSens HIV-1 RNA detection assays and expand its product offerings in the field of nucleic acid-sequence-based HIV assays. Following Bayer and Roche, the Dutch company becomes the third licensee for these Chiron HIV assays.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze